参考文献/References:
[1] American Diabetes Association.The expert committee on the diagnosis and classitication of diabetes mellitus:report of the export committee on the diagnosis and classification of diabete mellitus[J].Diabetes Care,1997,20:11831197.
[2] WHO.assessment of osteoportic fracture risk and its role in screening for postmenopausal osteoporosis[J]. WHO Technical Report Series,Geneva.
[3] Kanazawa I. Interaction between bone and glucose metabolism[J]. Endoc J,2017,64(11):10431053.
[4] Kanazawa I,Sugimoto T. Diabetes mellitusinduced bone fragility[J]. Intern Med,2018,57(19):27732785.
[5] 雷映红,陈 辉,刘 菊.老年男性2型糖尿病患者骨密度与炎症因子相关性研究[J].中国骨质疏松杂志,2017,23(2):213215.
[6] Schett G,David JP. The multiple faces of autoimmunemediated bone loss[J]. Nat Rev Endocrinol,2010,6(12):698706.
[7] Hygum K,StarupLinde J,Harslof T,et al. Mechanisms in endocrinology:diabetes mellitus,a state of low bone turnover a systematic review and metaanalysis[J]. Eur J Endocrinol,2017,176(3):137157.
[8] 贾 真,何 旺,张渭涛,等.2型糖尿病患者骨转换指标与血糖的相关性[J].陕西医学杂志,2017,46(8):10831084.
[9] Cortet B,Lucas S,LegrouxGerot I,et al. Bone disorders associated with diabetes mellitus and its treatments[J].Joint Bone Spine,2019,86(3):315320.
[10] 王 贺,王莲地,阳 琰,等. 2型糖尿病合并骨质疏松患者血清25羟维生素D、鸢尾素水平观察及其与骨密度的关系[J].中国糖尿病杂志,2018,26(7):569572.
[11] 柴 毅,樊巧玲.左归丸治疗骨质疏松症相关机制[J].中国实验方剂学杂志,2018,24(17):201208.
[12] Lombardi G,SanchisGomar F,Perego S,et al. Implications of exerciseinduced adipomyokines in bone metabolism[J]. Endocrine,2016,54(2):284305.
[13] Morley JE,Malmstrom TK,RodriguezManas L,et al.Frailty,sarcopenia and diabetes[J]. J Am Med Dir Assoc,2014,15(2):853859.
[14] 钟 文,谢春光,高 泓,等.糖尿病与肌少症关系研究新进展[J].中国糖尿病杂志,2017,25(7):662665.
[15] 胡咏新,郑仁东,范尧夫,等.左归丸对老龄糖尿病患者骨代谢及跌倒风险的观察研究[J].按摩与康复医学,2017,8(24):5154.
[16] Bettis T,Kim BJ,Hamrick MW. Impact of muscle atrophy on bone metabolism and bone strength:implications for musclebone crosstalk with aging and disuse[J]. Osteoporos Int,2018,29(8):17131720.
[17] 黄武维,杨 琳.电针结合补肾健脾方对老年骨质疏松患者骨密度及血钙和血清OPN水平的影响[J].陕西中医,2016,37(4):481483.